Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于深圳微芯生物科技股份有限公司股东向特定机构投资者询价转让股份的核查报告
Regulatory Filings Classification · 82% confidence The document is a detailed ‘核查报告’ (verification report) prepared by CITIC Securities for the Shanghai Stock Exchange, assessing compliance of a shareholder inquiry-based transfer under the Exchange’s STAR Market guidelines. It is not an annual or interim financial report, audit report, earnings release, dividend notice, management change announcement, or M&A filing. Nor is it a direct share issue by the company or buyback. Instead, it is a regulatory compliance document verifying procedures and results. Therefore it falls under the catch-all “Regulatory Filings” category.
2026-05-22 Chinese
股东询价转让结果报告书暨持股5%以上股东权益变动触及5%整数倍的提示性公告
Major Shareholding Notification Classification · 95% confidence The document details a block share transfer by existing significant shareholders (holding above 5%) and reports the post-transfer holdings crossing a 5% threshold. It is a notification of major shareholding changes (crossing threshold), matching the 'Major Shareholding Notification' category.
2026-05-22 Chinese
股东询价转让计划书
Major Shareholding Notification Classification · 78% confidence The document is a shareholder announcement of a planned secondary transfer of significant pre-IPO holdings (22,140,400 shares, 5% of total) by major shareholders via an inquiry-based transfer. It details the sellers, quantities, pricing principles, and lock-up terms. This is not a new issuance by the company, nor an earnings or annual report, but a notice of a material shareholding change by existing shareholders. It best fits the “Major Shareholding Notification” category.
2026-05-15 Chinese
自愿披露关于澳门药物监督管理局批准西格列他钠上市的公告
Regulatory Filings Classification · 75% confidence The document is a voluntary disclosure announcing Macau’s drug authority approval for a new pharmaceutical product. It contains no financial statements or investor presentation content, nor does it relate to dividends, share issues, voting, management changes, or any specific financial filings categories. It is a general corporate announcement of regulatory approval, fitting best into the fallback “Regulatory Filings” category.
2026-05-14 Chinese
关于收到国家知识产权局《无效宣告请求审查决定书》的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotech Co., Ltd. regarding the receipt of a decision from the National Intellectual Property Office about a patent invalidation request. It details the patent involved, the decision outcome, and the potential legal recourse. The content is a regulatory announcement about intellectual property legal proceedings and does not contain financial data, earnings, management changes, or other report types. It is not a full report but a regulatory update on legal matters. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is short and focused on legal proceedings, not a report publication or certification, so it is not RPA or RNS.
2026-05-08 Chinese
国投证券股份有限公司关于深圳微芯生物科技股份有限公司差异化分红事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (国投证券股份有限公司) regarding a differentiated dividend distribution matter for Shenzhen Microchip Biotechnology Co., Ltd. It discusses the company's share repurchase plans, the impact on dividend distribution, and compliance with relevant laws and regulations. The document includes specific financial figures related to share repurchases and dividend calculations but does not present a full financial report or earnings release. It is a formal opinion on a specific corporate action related to dividends and share repurchases, not a general financial report or earnings announcement. This type of document aligns best with Regulatory Filings (RNS), as it is a compliance and verification statement rather than a full report or announcement of voting results or capital changes.
2026-05-07 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.